Antisense Phase II Clinical Trial now 50% enrolled and on track for completion
Antisense Therapeutics (ASX:ANP) has provided a highly promising update on its Phase II clinical trial of its immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD).
The company has indicated that five patients are now enrolled in the nine patient trial, with four of these now being dosed with ANP’s ATL1102 treatment. The fifth patient has recently passed the eligibility criteria, and will commence their dosing schedule in early February.
No serious adverse events or affects have been reported to date during the trial, which is being conducted at the neuromuscular centre of the Royal Children’s Hospital in Melbourne (RCH) (which operates the largest DMD treatment clinic in the southern hemisphere).
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). Scientific literature has reported that patients who possess a greater number of T cells with high levels of CD49d on their surface, experience more severe and rapid disease progression.
ATL1102 is being developed as a novel treatment for the inflammation that exacerbates muscle fibre damage in DMD patients, currently treated with corticosteroids. Unfortunately, corticosteroids have a range of serious side effects when used for extended periods, which is required in DMD patients.
The main objective of the trial pertain to the safety and tolerability of ATL1102, with the effectiveness of its ability to reduce inflammation, muscle damage and disease progression to also be assessed.
ANP remains on track to have nine patients enrolled into the trial and have their dosing complete in Q3 2019. Trial results will follow, however earlier study read outs are possible (because the trial is an open label study).
US based DMD group Parent Project Muscular Dystrophy (PPMD), whose advocacy efforts have secured hundreds of millions of dollars in funding and secured two FDA approvals, have incorporated details on the ATL1102 for DMD trial on their website (which can be found below).
PPMD’s efforts are focused on advancing care and treatments for DMD by leveraging US federal resources, building partnerships and creating regulatory procedures and infrastructure.
Since its inception in 2000, PPMD has invested over US$50 million into DMD research and therapy development and aid in leveraging over US$500 million dedicated for DMD.
ANP CEO Mark Diamond spoke on the clinical trial update, “We are very pleased to see the ATL1102 listing by PPMD, the most prominent US DMD advocacy group, as it significantly increases visibility and awareness of ANP’s DMD clinical development activities in the US, the world’s largest pharmaceutical market.”
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.